Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.
Myers
Wendy
W
Newman
Marissa
M
Katz
Brian
B
Gottlieb
Alice B
AB
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D011040:Dermatitis, Toxicodendron / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D000068800:Etanercept; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000305:Adrenal Cortex Hormones; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept